CA2087883A1 - Beta-alethine use in cell culture and therapy - Google Patents
Beta-alethine use in cell culture and therapyInfo
- Publication number
- CA2087883A1 CA2087883A1 CA 2087883 CA2087883A CA2087883A1 CA 2087883 A1 CA2087883 A1 CA 2087883A1 CA 2087883 CA2087883 CA 2087883 CA 2087883 A CA2087883 A CA 2087883A CA 2087883 A1 CA2087883 A1 CA 2087883A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- alethine
- beta
- mammal
- immunocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
.beta.-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of .beta.-alethine in the treatment of immune disorders and diseases, especially neoplasia, and in the promotion of cell cultures.
.beta.-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of .beta.-alethine in the treatment of immune disorders and diseases, especially neoplasia, and in the promotion of cell cultures.
Claims (15)
1. A method for regulating cell function or bioproduction comprising exposing the cell, in vitro or in vivo, to an amount of .beta.-alethine, or physiologically compatible salt thereof, sufficient to normalize or improve function or bioproduction of the cell.
2. The method of Claim 1, wherein the cell is mammalian, including a human cell.
3. The method of Claim 2, wherein the cell is infected with a pathogen, including a virus.
4. The method of Claim 2, wherein the cell is an immunocyte or a neoplastic cell.
5. The method of Claim 1, wherein the cell is an immunocyte exposed to sufficient .beta.-alethine to normalize or improve immunological surveillance.
6. The method of Claim 1, wherein the cell is exposed, in vitro, to from at least about 10 pg .beta.-alethine/ml cell culture, or, in vivo, from at least about 10 pg .beta.-alethine/kg weight of the organism.
7. A method for treating neoplasia in a mammal, including a human, comprising administering to the mammal .beta.-alethine, or a physiologically compatible salt thereof, in an amount suffi-cient to reduce tumor burden, induce regression of the tumor, or inhibit tumor growth or metastasis, optionally in conjunction with debulking of a tumor.
8. The method of Claim 7, wherein the neoplasia is hematolymphoid.
9. A method for treating immune disease or disorder in a mammal, including a human, comprising administering to the mammal .beta.-alethine, or a physiologically compatible salt thereof, in an amount sufficient to improve or normalize immunological function or bioproduction in the mammal.
10. The method of Claim 9, wherein the immune disease or disorder is an autoimmune disease or disorder, or an immunodefi-ciency disease or disorder, including AIDS or hypogammaglobuli-nemia.
11. The method of Claim 1 for improving or normalizing immunocyte function or bioproduction in a mammal, including a human, comprising extracting an immunocyte from the mammal, exposing the immunocyte, in vitro, or sufficient .beta.-alethine to stimulate immune function or bioproduction thereof, and thereaf-ter reintroducing the stimulated immunocyte into the afflicted mammal.
12. The method of Claim 11, wherein the mammal is afflicted with neoplasia, and the immunocyte is additionally stimulated by exposure to the neoplastic cell prior to the reintroduction of the immunocyte into the mammal.
13. A method for delaying the onset of senescence comprising exposing a presenescent cell, in vivo or in vitro, to .beta.-alethine in an amount sufficient to delay senescence thereof.
14. A method for adapting a culture-resistant cell of an organism to culture, comprising exposing the resistant cell, in vivo or in vitro, to .beta.-alethine in an amount sufficient to adapt the cell to culture.
15. The method of Claim 1, wherein a cell of an organism is additionally exposed to at least one factor which promotes either the maintenance or growth of the cell, or both.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002481077A CA2481077A1 (en) | 1992-07-27 | 1993-01-22 | Beta-alethine use in cell culture and therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91925392A | 1992-07-27 | 1992-07-27 | |
US07/919,253 | 1992-07-27 | ||
US92497792A | 1992-08-05 | 1992-08-05 | |
US07/924,977 | 1992-08-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002481077A Division CA2481077A1 (en) | 1992-07-27 | 1993-01-22 | Beta-alethine use in cell culture and therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2087883A1 true CA2087883A1 (en) | 1994-01-28 |
CA2087883C CA2087883C (en) | 2010-09-14 |
Family
ID=27129768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2087883 Expired - Lifetime CA2087883C (en) | 1992-07-27 | 1993-01-22 | Beta-alethine use in cell culture and therapy |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2087883C (en) |
-
1993
- 1993-01-22 CA CA 2087883 patent/CA2087883C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2087883C (en) | 2010-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koenig et al. | Bacterial lipopolysaccharide activates suppressor B lymphocytes. | |
CN103736207B (en) | A kind of based on the synergistic bone injury/osteoporosis therapeutic bed of many physical agents | |
EP0308197A3 (en) | Method for stimulating the immune system | |
Dwarakanath et al. | Modification of the radiation induced damage by 2-deoxy-D-glucose in organ cultures of human cerebral gliomas | |
Argall et al. | Interactions between CD4+ T-cells and rat Schwann cells in vitro: 1. Antigen presentation by Lewis rat Schwann cells to P2-specific CD4+ T-cell lines | |
CA2087883A1 (en) | Beta-alethine use in cell culture and therapy | |
GR3018632T3 (en) | Beta-alethine use in cell culture and therapy. | |
RU94022481A (en) | Method of estimation of immunogenic activity of bioactive compounds and composition for its realization | |
HU189706B (en) | Improved process for the production of interferon | |
Lamberts et al. | Effect of cyproheptadine, desmethylcyproheptadine, γ-amino-butyric acid and sodium valproate on adrenocorticotrophin secretion by cultured pituitary tumour cells from three patients with Nelson's syndrome | |
Holmes et al. | The radiation dose-rate effect in two human neuroblastoma cell lines | |
Cory et al. | Calcium ion-dependent proliferation of L1210 cells in culture | |
Cercek et al. | Induction of PHA response in mouse bone marrow cells by thymic extracts as studied by changes in the structuredness of cytoplasmic matrix. | |
Barkley Jr et al. | Volume and time factors in interstitial gamma-ray therapy | |
Zhong et al. | Control and surveillance of filariasis in Shandong | |
CN103736209A (en) | Osteoporosis treatment bed based on medium wave ultraviolet light exposure | |
Giacovazzo et al. | Relationship between HLA system in cluster headache and clinical response to lithium therapy | |
Morgan et al. | Malignancy in vivo of chick embryo cells infected with Rous sarcoma virus in vitro | |
JPS6461420A (en) | Alpha-ethiocholanedione drug, and method of causing high hematic concentration alpha-ethiocholanone | |
Laude et al. | Isoprinosine trial in herpes zoster. Effects on delayed cutaneous hypersensitivity | |
Ahrorovna | Morphological Features of Lymphoid Structures of the Small Intestine of Rats in Norm and Chronic Radiation Sickness | |
Levo et al. | Increased incidence of urethane induced lung adenomata by autosensitized lymphocytes | |
Wierowski et al. | Critical periods during the in situ repair of radiation-induced DNA damage in rat cerebellar neurons and 9L brain tumor cells | |
Galbraith | Effect of lithium on colony formation and production of colony-stimulating factor | |
Naumov et al. | Autonomous device for photostimulation of the gastrointestinal tract immunity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDC | Correction of dead application (reinstatement) | ||
MKEX | Expiry |
Effective date: 20130122 |